Genzyme supplies rise, but Fabrazyme lags

Within Sanofi's ($SNY) financial news of last week--7% sales growth--are some stellar Genzyme stats resulting from the greater availability of some of its products. With supplies improving as Genzyme works its way through a manufacturing consent decree with the FDA, the unit saw a 58% increase in Cerezyme sales and a 42% rise in Myozyme.

Fabrazyme, its treatment for the enzyme disorder Fabry disease, continues to slug its way through remediation, up just 3.5% from the second quarter of 2010. Sanofi says the modest increase reflects continued supply constraints.

Genzyme will remain unable to boost Fabrazyme production until its new facility in Framingham, MA comes online. The company expects that the first quarter of 2012 is the soonest that could happen, reports MedPage Today, indicating a slippage from the late 2011 timeframe it projected at the beginning of the year.

The drug is currently produced in limited quantities at other Genzyme facilities.

- see the story
- here's the Sanofi release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.